The treatment of RA neutrophils with IL-6 or PMA induced an increase of NETosis formation that was prevented by the combined treatment of tocilizumab plus IL-6 or PMA generated, suggesting that tocilizumab might prevent NETosis in RA patients. The gene discussed is IL6; the disease is rheumatoid arthritis.